Brainstorm Cell Therapeutics Inc. ( BCLI) - Key Metrics
BCLI Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.35 | -$0.08 | -$0.08 |
| 2026Q1 | $0 | -$0.19 | -$0.12 | -$0.12 |
| 2025Q4 | $0 | -$0.26 | -$0.08 | -$0.08 |
| 2025Q3 | $0 | -$0.19 | -$0.10 | -$0.10 |
| 2025Q2 | $0 | -$0.34 | -$0.41 | -$0.41 |
BCLI Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -0.71 |
| 2026Q1 | 0% | -1.25 |
| 2025Q4 | 0% | -0.63 |
| 2025Q3 | 0% | -0.93 |
| 2025Q2 | 0% | -0.82 |
BCLI
Price: $0.94
52 week price:
Earnings Per Share: -0.88 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 566900
Ebitda: -2.4 millionMarket Capitalization: 10.3 million